DrugPatentWatch Database Preview
Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Biologic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Tradenames: | 1 |
| Patents: | 5 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
Patent Text Search: US Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | Chevron Phillips Chemical Company LP (The Woodlands, TX) | 2031-06-06 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2029-05-13 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | ALDERBIO HOLDINGS LLC (Las Vegas, NV) | 2028-11-25 | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | Start Trial | Progenra, Inc. (Malvern, PA) The Children\'s Hospital of Philadelphia (Philadelphia, PA) | 2035-07-31 | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20120118088 | Start Trial |
| China | 102292106 | Start Trial |
| South Africa | 200908770 | Start Trial |
| Singapore | 171804 | Start Trial |
| China | 102292449 | Start Trial |
| Japan | 2010528589 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016000086 | Germany | Start Trial | PRODUCT NAME: ALBUMINFUSIONSPROTEINE AUFWEISEND FAKTOR IX FUSIONIERT MIT HUMANEM ALBUMIN; REGISTRATION NO/DATE: EU/1/16/1095 20160511 |
| C/GB02/026 | United Kingdom | Start Trial | PRODUCT NAME: ANAKINRA (ALSO KNOWN AS HUMAN IL-1RA); REGISTERED: UK EU/1/02/203/001 20020308; UK EU/1/02/203/002 20020308; UK EU/1/02/203/003 20020308; UK EU/1/02/203/004 20020308 |
| 2016000049 | Germany | Start Trial | PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621 |
| 30/2001 | Austria | Start Trial | PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1) |
| 2015 00043 | Denmark | Start Trial | PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826 |
| /2001 | Austria | Start Trial | PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1); REGISTRATION NO/DATE: EU/1/01/179/001 20010517 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
